QC6352

QC6352 is an orally active KDM4 inhibitor with anti-tumor and anti-proliferative activity. QC6352 has in vivo inhibitory effects on PDX models of breast and colon cancer and reduces the number of chemoresistant cell populations. QC6352 inhibits KDM4 different isoforms with IC50s of 104 nM (KDM4A), 56 nM (KDM4B), 35 nM (KDM4C), and 104 nM (KDM4D), respectively. QC6352 has moderate inhibitory activity against KDM5 with an IC50 of 750 nM (KDM5B) [1][2].

Product Specifications

CAS Number

[1851373-36-8]

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Histone Demethylase

Type

Reference compound

Related Pathways

Epigenetics

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/QC6352.html

Purity

99.13

Solubility

DMSO : 16.67 mg/mL (ultrasonic)

Smiles

O=C(C1=C(NC[C@@H]2CCCC3=C2C=CC(N(C)C4=CC=CC=C4)=C3)C=NC=C1)O

Molecular Formula

C24H25N3O2

Molecular Weight

387.47

Precautions

H302, H315, H319, H335

References & Citations

[1]Chen YK, et al. Design of KDM4 Inhibitors with Antiproliferative Effects in Cancer Models. ACS Med Chem Lett. 2017 Jul 27;8 (8) :869-874.|[2]Metzger E, et al. KDM4 inhibition targets breast cancer stem-like cells. Cancer Res. 2017 Sep 7. pii: canres.1754.